Page 30 of 31

PH4.1-11 | Cardiovascular and Blood Pharmacology — Assignment

Grading Rubric — Cardiovascular and Blood Pharmacology — Assignment Rubric

Criterion	Points	Full-marks descriptor
Antihypertensive selection and renoprotection rationale (PH4.6/PH4.7)	4 pts	Exceeds: Correctly selects ACEi/ARB with precise mechanistic explanation (efferent arteriolar dilation, reduced intraglomerular pressure, proteinuria reduction), accurate monitoring (K+, creatinine at 1-2 weeks), and addresses K+ concern with existing K+ of 4.8.
HFrEF four-pillar GDMT with mechanistic understanding (PH4.9)	6 pts	Exceeds: Names all four pillars (ACEi/ARNI, beta-blocker, MRA, SGLT2i) with correct examples, accurately explains neurohormonal blockade mechanism for each, correctly identifies euvolaemia requirement for beta-blocker initiation, and identifies spironolactone (MRA) for post-MI EF ≤40% (EPHESUS trial).
Anticoagulation decision-making in AF with CKD (PH4.2)	5 pts	Exceeds: Correctly identifies anticoagulation indication (CHA₂DS₂-VASc ≥2), clearly compares warfarin vs DOAC with preference for DOAC (convenience, predictable pharmacokinetics, no INR monitoring), identifies dose-adjusted DOAC for eGFR 52 (e.g., rivaroxaban 15 mg OD or apixaban 5 mg BD — no dose reduction needed for apixaban at this eGFR; correct renal thresholds stated), relevant monitoring (renal function) and bleeding risk factor (e.g., uncontrolled hypertension, concurrent NSAID).
Statin mechanism, myopathy management, and secondary prevention alternatives (PH4.11)	5 pts	Exceeds: Accurately explains HMG-CoA reductase inhibition and LDL receptor upregulation; correctly classifies CK 2.1× ULN with symptoms as myositis (dose reduction warranted); names two correct interactions (e.g., gemfibrozil + CYP3A4 inhibitors/amiodarone) with mechanism; identifies ezetimibe or PCSK9 inhibitor as appropriate add-on.